Please assess the completion status of the following clinical trial:

Trial Title: Memantine Augmentation in Obsessive-Compulsive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* at least 18 years of age~* suffering from OCD~* Y-BOCS score of 18 or greater~* taking a therapeutic dose of an anti-OCD medication specified in the protocol~Exclusion Criteria:~* diagnosed with a mental disorder other than OCD~* taking tiagabine or pregabalin~* having had a previous trial of memantine~* receiving therapy for OCD~* substance abuse in the last 6 months~* personality disorders sufficiently severe to interfere with study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Memantine open label (Type: EXPERIMENTAL): All subjects knowingly received (open label) memantine for up to 12 weeks with a target dose of 10 mg twice a day (20mg/d) taken orally.

Based on this trial design, predict the completion outcome and termination type (if applicable).